Literature DB >> 22718050

Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY Study): rationale and study design.

G P Rossi1, T M Seccia, V Gallina, M L Muiesan, L Leoni, M Pengo, F Ragazzo, P Caielli, A Belfiore, G Bernini, F Cipollone, S Cottone, C Ferri, G Giacchetti, G Grassi, C Letizia, M Maccario, O Olivieri, G Palumbo, D Rizzoni, E Rossi, L Sechi, M Volpe, F Mantero, A Morganti, A C Pessina.   

Abstract

Primary aldosteronism (PA) is the most common endocrine form of hypertension and may carry an increased risk of atrial flutter or fibrillation (AFF). The primary goal of this multicentre cohort study is thus to prospectively establish the prevalence of PA in consecutive hypertensive patients referred for lone (non-valvular), paroxysmal or permanent AFF. Secondary objectives are to determine: (1) the predictors of AFF in patients with PA; (2) the rate of AFF recurrence at follow-up after specific treatment in the patients with PA; (3) the effect of AFF that can increase atrial natriuretic peptide via the atrial stretch and thereby blunt aldosterone secretion, on the aldosterone-to-renin ratio (ARR), and thus the case detection of PA; (4) the diagnostic accuracy of ARR based on plasma renin activity or on the measurement of active renin (DRA) for diagnosing PA in AFF patients. Case detection and subtyping of PA will be performed according to established criteria, including the 'four corners criteria' for diagnosing aldosterone-producing adenoma. Pharmacologic or direct current cardioversion will be undertaken whenever indicated following current guidelines. The hormonal values and ARR will be compared within patient between AFF and sinus rhythm. Organ damage, cardiovascular events and recurrence of AFF will also be assessed during follow-up in patients with PA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22718050     DOI: 10.1038/jhh.2012.21

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  13 in total

Review 1.  Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

Authors:  Fadia Mayyas; Karem H Alzoubi; David R Van Wagoner
Journal:  Int J Cardiol       Date:  2013-08-15       Impact factor: 4.164

Review 2.  Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble.

Authors:  Teresa M Seccia; Brasilina Caroccia; Gail K Adler; Giuseppe Maiolino; Maurizio Cesari; Gian Paolo Rossi
Journal:  Hypertension       Date:  2017-04       Impact factor: 10.190

Review 3.  Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.

Authors:  Satoshi Morimoto; Atsuhiro Ichihara
Journal:  Hypertens Res       Date:  2020-05-18       Impact factor: 3.872

Review 4.  Arterial Hypertension, Aldosterone, and Atrial Fibrillation.

Authors:  Teresa M Seccia; Brasilina Caroccia; Giuseppe Maiolino; Maurizio Cesari; Gian Paolo Rossi
Journal:  Curr Hypertens Rep       Date:  2019-11-18       Impact factor: 5.369

Review 5.  Anti-arrhythmic strategies for atrial fibrillation: The role of computational modeling in discovery, development, and optimization.

Authors:  Eleonora Grandi; Mary M Maleckar
Journal:  Pharmacol Ther       Date:  2016-09-06       Impact factor: 12.310

Review 6.  Atrial Fibrillation and Its Association with Endocrine Disorders.

Authors:  Manjari Devidi; Avanija Buddam; Sunil Dacha; D Sudhaker Rao
Journal:  J Atr Fibrillation       Date:  2014-02-28

7.  Screening for secondary endocrine hypertension in young patients.

Authors:  Raluca Trifanescu; Mara Carsote; Andra Caragheorgheopol; Dan Hortopan; Anda Dumitrascu; Mariana Dobrescu; Catalina Poiana
Journal:  Maedica (Buchar)       Date:  2013-06

8.  Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.

Authors:  Gregory L Hundemer; Gary C Curhan; Nicholas Yozamp; Molin Wang; Anand Vaidya
Journal:  Lancet Diabetes Endocrinol       Date:  2017-11-09       Impact factor: 32.069

Review 9.  Evolution of the Primary Aldosteronism Syndrome: Updating the Approach.

Authors:  Anand Vaidya; Robert M Carey
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

10.  The Challenges of Arterial Hypertension.

Authors:  Gian Paolo Rossi
Journal:  Front Cardiovasc Med       Date:  2015-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.